Table 3.

Demographic characteristics, diagnosis, and treatment exposures for 276 adult survivors of childhood cancer treated with radiation therapy that included the ear.

Characteristics	All Survivors	Audiology	Severe Hearing Loss
	N = 276	n = 51	n = 19
Age at first diagnosis (years)
Median	10.1	8.4	8.0
Range	0–21.8	0–21.1	0–19.2
Sex (number, %)
Male	163 (59.1)	27 (52.9)	11 (57.9)
Female	113 (40.9)	24 (47.1)	8 (42.1)
Ethnicity (number, %)
White	8 (2.9)	37 (72.5)	10 (52.6)
Hispanic	215 (77.9)	3 (5.9)	2 (10.5)
African American	19 (6.9)	3 (5.9)	2 (10.5)
Asian	18(6.5)	5 (9.8)	3 (15.8)
Did not identify or other	16 (5.8)	3 (5.9)	2 (10.5)
Diagnosis (number, %)
Leukemia	154 (55.8)	22 (43.1)	7 (36.8)
Lymphoma	19 (6.9)	2 (3.9)	0
Rhabdomyosarcoma of head and neck	22 (8.0)	6 (11.8)	2 (10.5)
Retinoblastoma	18 (6.5)	3 (5.9)	2 (10.5)
Other sarcoma	9 (3.2)	2 (3.9)	0
Nasopharyngeal carcinoma	2 (0.7)	2 (3.9)	0
Medulloblastoma	10 (3.6)	4 (7.8)	2 (10.5)
Astrocytoma	11(3.9)	3 (5.9)	0
Ependymoma	2 (3.9)	1 (2.0)	1 (5.3)
CNS germ cell tumor	5 (1.8)	1 (2.0)	0
Other CNS tumors	5 (1.8)	4 (7.8)	5 (26.3)
Other	20 (7.2)	1 (2.0)	0
Follow up in ALTFU (years)
Median	3.0	4.3	5.3
Range	0–11.1	0–10.1	0–9.9
Audiology follow-up (years)
Median		15.1	16.6
Range		0–55.1	0–55.1
Age at first post-treatment audiogram (years)
Median	N/A	19.4	20.0
Range	N/A	7.2–55.1	8.3–55.1
Time from diagnosis to first post-treatment audiogram (years)
Median	N/A	7.9	9.1
Range	N/A	0.7–55.1	0.7–55.1
Hearing aids (Number, %)	13 (4.7)	10(19.6)	10 (52.6)
Hematopoietic cell transplant	108 (39.1)	1 (2.0)	0
CSF shunt	18(16.5)	3 (5.9)	0
Cranial surgery	42 (15.2)	13 (25.5)	8 (42.1)

ALTFU: Adult Long-Term Follow-Up; CNS: central nervous system; CSF: craniospinal fluid; N/A: not applicable.